Celularity (NASDAQ:CELU) Sees Strong Trading Volume

Shares of Celularity Inc. (NASDAQ:CELUGet Rating) saw unusually-strong trading volume on Tuesday . Approximately 10,308 shares were traded during trading, a decline of 95% from the previous session’s volume of 199,647 shares.The stock last traded at $11.04 and had previously closed at $10.65.

A number of analysts have recently issued reports on CELU shares. Truist Financial cut Celularity from a “buy” rating to a “hold” rating and set a $10.00 price objective on the stock. in a research report on Wednesday, April 6th. Oppenheimer boosted their price objective on Celularity from $9.00 to $10.00 in a research report on Friday, April 1st. Finally, Zacks Investment Research cut Celularity from a “buy” rating to a “hold” rating in a research report on Monday, April 4th.

The business’s fifty day moving average price is $7.72. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.28.

Celularity (NASDAQ:CELUGet Rating) last released its quarterly earnings data on Thursday, March 31st. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.28. Equities analysts expect that Celularity Inc. will post -1.26 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC acquired a new stake in shares of Celularity during the fourth quarter worth about $48,000. Marshall Wace LLP bought a new position in Celularity in the third quarter valued at approximately $87,000. Penserra Capital Management LLC bought a new position in Celularity in the third quarter valued at approximately $88,000. Millennium Management LLC bought a new position in Celularity in the third quarter valued at approximately $109,000. Finally, Caption Management LLC bought a new position in Celularity in the third quarter valued at approximately $142,000. 11.46% of the stock is currently owned by institutional investors.

About Celularity (NASDAQ:CELU)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic T cell therapies. It operates through Cell Therapy, Degenerative Disease, and BioBanking. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T therapy, which is in pre-clinical stage for the treatment of B-cell malignancies; CYNK-001, an allogeneic unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell to treat HER2+ gastric cancer; and APPL-001, a placenta-derived mesenchymal-like adherent stromal cell for the treatment of crohn's disease.

Further Reading

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.